Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Sickle-cell Disease
NCT06975865Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Annualized rate of clinical vaso-occlusive crises (VOC) at 52 weeks. Started Aug 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06975865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975865.